Related Experiment Video
Updated: Aug 11, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Imaging and biophysical modelling of thrombogenic mechanisms in atrial fibrillation and stroke
Ahmed Qureshi1, Gregory Y H Lip2, David A Nordsletten1,3
1School of Biomedical Engineering and Imaging Sciences, King's College London, St. Thomas' Hospital, London, United Kingdom.
Insights
Atrial fibrillation (AF) increases stroke risk, primarily from the left atrial appendage. New imaging and modeling techniques aim to better predict clot formation and personalize stroke risk in AF patients.
Area of Science:
- Cardiovascular Medicine
- Biophysics
- Medical Imaging
Background:
- Atrial fibrillation (AF) is a major cause of ischemic stroke, with the left atrial appendage (LAA) as the main source of blood clots.
- Current stroke risk scores (e.g., CHA2DS2-VASc) do not fully capture thrombogenic mechanisms like blood stasis, hypercoagulability, and endothelial dysfunction (Virchow's triad).
- There is a clinical need to assess thrombogenicity in AF patients before thrombus formation occurs.
Purpose of the Study:
- To review advancements in cardiac imaging and in-silico biophysical modeling for understanding thrombogenesis in AF.
- To highlight the limitations of current methods and the potential of integrated approaches for stroke risk stratification.
Main Methods:
- Cardiac imaging techniques (CT, MRI, echocardiography) for measuring blood flow and identifying LA fibrosis.
- In-silico modeling using computational fluid dynamics and reaction-diffusion-convection equations to simulate blood flow and coagulation.
- Exploration of surrogate flow metrics for endothelial damage assessment.
Main Results:
- Cardiac imaging can assess blood flow and LA fibrosis but has limitations in evaluating blood coagulation dynamics.
- In-silico modeling provides mechanistic insights into thrombogenesis and has advanced understanding of coagulation.
- Neither imaging nor modeling alone fully elucidates AF-related thrombogenicity.
Conclusions:
- Combining cardiac imaging with in-silico modeling offers a more comprehensive approach to assessing thrombogenicity.
- Future integration of machine learning with these techniques could enable rapid, personalized stroke risk stratification in AF patients.
- Rigorous verification and clinical validation are essential for developing these advanced tools.
Abstract:
Atrial fibrillation (AF) underlies almost one third of all ischaemic strokes, with the left atrial appendage (LAA) identified as the primary thromboembolic source. Current stroke risk stratification approaches, such as the CHA2DS2-VASc score, rely mostly on clinical comorbidities, rather than thrombogenic mechanisms such as blood stasis, hypercoagulability and endothelial dysfunction-known as Virchow's triad. While detection of AF-related thrombi is possible using established cardiac imaging techniques, such as transoesophageal echocardiography, there is a growing need to reliably assess AF-patient thrombogenicity prior to thrombus formation. Over the past decade, cardiac imaging and image-based biophysical modelling have emerged as powerful tools for reproducing the mechanisms of thrombogenesis. Clinical imaging modalities such as cardiac computed tomography, magnetic resonance and echocardiographic techniques can measure blood flow velocities and identify LA fibrosis (an indicator of endothelial dysfunction), but imaging remains limited in its ability to assess blood coagulation dynamics. In-silico cardiac modelling tools-such as computational fluid dynamics for blood flow, reaction-diffusion-convection equations to mimic the coagulation cascade, and surrogate flow metrics associated with endothelial damage-have grown in prevalence and advanced mechanistic understanding of thrombogenesis. However, neither technique alone can fully elucidate thrombogenicity in AF. In future, combining cardiac imaging with in-silico modelling and integrating machine learning approaches for rapid results directly from imaging data will require development under a rigorous framework of verification and clinical validation, but may pave the way towards enhanced personalised stroke risk stratification in the growing population of AF patients. This Review will focus on the significant progress in these fields.

